Table 1 PD-L1degradation and antitumor activity.
From: PD-L1 degradation pathway and immunotherapy for cancer
Degradation by | Regulatory signal | Therapy | Caner types | Reference |
|---|---|---|---|---|
Proteasome | EGFR/GSK3β | Osimertinib | NSCLC | |
Proteasome | mTORC2/Akt/GSK3β | MTI-31 | NSCLC | |
Proteasome | ATR | VE822 | Breast cancer | |
Lysosome | PKCα/GSK3β/MITF | SA-49 | NSCLC | |
Lysosome | Sigma 1 | IPAG | Prostate cancer, TNBC | |
Lysosome | ZDHHC3 | 2-BP | Colon cancer | |
Lysosome | HIP1R | PD-LYSO | Colon cancer |
